Soluble Fas affects erythropoiesis in vitro and acts as potential predictor of erythropoiesis-stimulating agents therapy in chronic kidney disease patients

Serum soluble Fas levels (sFas) is associated to erythropoietin (Epo) hyporesponsiveness in patients with chronic kidney disease (CKD). If sFas could predict the need for erythropoiesis-stimulating...